📈 Join us for LIVE TRADING action all day long in the 📈

 Market Master’s trading room

Now, at absolutely no cost to our readers

Just one click, and you’re in!

As I look at the market right now, it sure looks like things are going to take a pause.

We have been enjoying an incredible rally over the last few weeks that caught many traders by surprise.

I think this is near the short-term top, and trading large-cap stocks is going to be tough for a while.

This is the perfect time to start looking at other opportunities in the market that have strong momentum pushing them higher.

Today, I want to talk to you about an idea I think is on the brink of something big.

Go to your favorite platform and pull up Citius Pharmaceuticals (CTXR) right now.

There aren’t many stocks with this kind of momentum right now.

Since last week’s low, CTXR has managed to rally over 50% higher.

What I like best is that this didn’t happen all in one day.  This has been a gradual buildup of upward pressure on the stock over several days, with “smaller” gains of around 10% a day.

Check out this chart and see what I mean….

I don’t like to speculate too much, but when I see a massive volume bar on a down day like we saw on CTXR last week, that is typically very close to the “panic lows.”

That is where big traders throw in the towel, and give up on something.

Often, it creates a very good buying opportunity.

The reason is that at the “panic lows,” all the sellers have been exhausted.

At the same time, there are usually a ton of short sellers who have bet the stock would go lower (and they are usually right!)

But, shorts have to cover their positions at some time.  When the volume dries up, and the price starts to reverse course, this begins to put a lot of pressure on traders with short bets against a stock.

I think that is a very acute possibility with CTXR right now.

We might be seeing a short squeeze in the works, and if that happens, who knows where it could go?

Now, I don’t know this for sure, and there is no way to prove anything.  It is just my hunch after trading the markets for over 20 years.  I have seen this a lot.

No matter what you do, it is very important to approach each trade you make with a solid game plan that keeps your risk to a minimum and enables you to capture profits if they appear.

All of this being said, I think today is a crucial day to watch CTXR.

I think this is a terrific time to start watching CTXR, if you have not been doing so already.

The few analysts covering CTXR are also very upbeat on it, with two of them reiterating their buy ratings and $4.00 12-month price targets in late May — more than 500% upside from yesterday’s closing price.

Check this out from the Wall Street Journal today…

Company insiders are also bullish (of course), but unlike most insiders who just talk a big game, they have actually been putting their money where their mouth is.

Co-founder and CEO Leonard Mazur has invested $22.5 million, and co-founder and Executive Vice Chairman Myron Holubiak has put in $4 million.

I love companies where management has that type of “skin in the game.” 

And Simply Wall St. wrote in February that “Citius Pharmaceuticals is bordering on breakeven, according to the 3 American Pharmaceuticals analysts. They anticipate the company to incur a final loss in 2024, before generating positive profits of $1.2m in 2025.”

Here are some great points on CTXR I found as you are starting your research today…

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company with a diversified pipeline and several near-term catalysts.

Its lead candidate is Mino-Lok, which, if approved — and that’s looking increasingly likely — would be the first and only FDA-approved antibiotic lock solution for salvaging “Central Venous Catheters” (CVCs).

That may not sound like the most exciting thing, but it would actually be a really huge deal.

For those who don’t know, CVCs are thin tubes that are inserted into large veins in the chest, neck, or groin.

They’re used to provide patients with medications, fluids, and nutrition and for regular blood sampling.

Every year, 7 million CVCs are used in the U.S., and 4 million of those are long-term, meaning they get used longer than a month.

Each year, approximately 500,000 of these catheters become infected, resulting in conditions known as central line-associated bloodstream infection (CLABSI) and catheter-related bloodstream infection (CRBSI).

The standard “cure” for CLABSI/CRBSI is for the patient to take a round of antibiotics and have the CVC removed and replaced.

The problem is it is extremely painful and traumatizing to remove/replace a CVC, and it can interrupt care for the patient’s underlying condition…

(Many of these patients are undergoing chemotherapy, etc.)

The procedure can also result in complications such as scarring, stenosis, and thrombosis, and in some patients it can be difficult to find a suitable site for the new catheter.

It’s also very expensive, costing approximately $10,000.

CTXR is hoping to replace this standard of care with Mino-Lok, an antibiotic solution intended to actually salvage infected catheters.

Mino-Lok has gone through a complete Phase 3 trial and the company reported topline results on May 21, noting that it had achieved the primary endpoint and several secondary endpoints with very high statistical significance.

Citius CEO Leonard Mazur said the CTXR is “extremely pleased by the strong results,” and that the company will prepare the full data analysis in the next few months, then will meet with the FDA to discuss the path to NDA submission and commercialization.

The company estimates the potential market for Mino-Lok at more than $1 billion in the U.S. and $2 billion globally.

CTXR’s other late-stage candidate is LYMPHIR, a purified reformulation of a previously FDA-approved cancer immunotherapy for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL).

CTCL is a condition that affects roughly 3,000 patients each year and that results in skin symptoms ranging from scaly patches to plaques and tumors.

LYMPHIR has also gone through a Phase 3 trial, reaching a 36.2% Objective Response Rate (ORR) and yielding a complete response, partial response, or durable stable disease in nearly half of the patients.

LYMPHIR has been granted orphan drug designation (ODD) by the FDA for the treatment of CTCL. If the drug is approved, that will give CTXR the possibility of seven years of market exclusivity.

CTXR submitted a Biologics License Application (BLA) to the FDA in March, and the FDA has said it will complete its review by August 13, 2024 — giving the company a strong near-term potential catalyst.

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: This is not your typical early-stage biotech stock. CTXR is a more developed company than most small-cap pharma stocks you have probably seen in the past.

They have a great management team that has committed a considerable amount of their personal wealth to this company.  The stock is clearly in “rally mode,” as it has gained over 50% the past few days.  

You never know how far a rally like this will last, but I think it is a great time to start watching CTXR right now.

I also found this very interesting graphic on their company website. It tells the story very well at a quick glance…

This is definitely a stock you need to look into right now.

To Your Success,

Jeff Bishop

P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.



*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on July 11, 2024. Previously, we received fifteen thousand dollars via ach bank transfer by Lifewater Media for advertising Citius Pharmaceuticals for a one marketing program on March 9th, 2023. These amounts were paid by someone else not connected to Citius Pharmaceuticals. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Citius Pharmaceuticals might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.